Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem ...
The biggest stories of the day delivered to your inbox.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback